Clinica Ostetrica e Ginecologica I, Istituto Luigi Mangiagalli, University of Milano, Milan, Italy
|
|
- Angel Norris
- 6 years ago
- Views:
Transcription
1 FERTILITY AND STERILITY VOL. 80, NO. 2, AUGUST 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study Paolo Vercellini, M.D., Giada Frontino, M.D., Olga De Giorgi, M.D., Giorgio Aimi, M.D., Barbara Zaina, M.D., and Pier Giorgio Crosignani, M.D. Clinica Ostetrica e Ginecologica I, Istituto Luigi Mangiagalli, University of Milano, Milan, Italy Objective: To determine whether the frequency and severity of dysmenorrhea are reduced in women with symptomatic endometriosis in whom a levonorgestrel-releasing intrauterine device (Lng-IUD) is inserted after operative laparoscopy compared with those treated with surgery only. Design: Open-label, parallel-group, randomized, controlled trial. Setting: A tertiary care and referral center for patients with endometriosis. Patient(s): Parous women with moderate or severe dysmenorrhea undergoing first-line operative laparoscopy for symptomatic endometriosis. Intervention(s): Randomization to immediate Lng-IUD insertion or expectant management after laparoscopic treatment of endometriotic lesions. Main Outcome Measure(s): Proportions of women with recurrence of moderate or severe dysmenorrhea in the two study groups 1 year after surgery and overall degree of satisfaction with treatment. Result(s): Moderate or severe dysmenorrhea recurred in 2 of 20 (10%) subjects in the postoperative Lng-IUD group and 9/20 (45%) in the surgery-only group. Thus, a medicated device inserted postoperatively will prevent the recurrence of moderate or severe dysmenorrhea in one out of three patients 1 year after surgery. A total of 15/20 (75%) women in the Lng-IUD group and 10/20 (50%) in the expectant management group were satisfied or very satisfied with the treatment received. Conclusion(s): Insertion of an Lng-IUD after laparoscopic surgery for symptomatic endometriosis significantly reduced the medium-term risk of recurrence of moderate or severe dysmenorrhea. (Fertil Steril 2003; 80: by American Society for Reproductive Medicine.) Key Words: Endometriosis, dysmenorrhea, pelvic pain, IUD, progestins Received September 9, 2002; revised and accepted January 14, Prize paper presented at the 8th World Congress on Endometriosis, San Diego, California, February 24 27, Reprint requests: Paolo Vercellini, M.D., Clinica Ostetrica e Ginecologica I, Istituto Luigi Mangiagalli, Università di Milano, Via Commenda 12, 20122, Milan, Italy (FAX: ; paolo. vercellini@unimi.it) /03/$30.00 doi: /s (03) Dysmenorrhea is the most frequent complaint reported by women with endometriosis (1). Laparoscopic surgery is often the treatment of choice for symptomatic disease, but results are not always satisfactory and pain recurrence is common (2, 3). Postoperative medical therapy should theoretically induce resorption of microscopic foci and of lesions that could not be removed, reduce the risk of iatrogenic dissemination of endometriotic cells, and improve pain relief. However, the available evidence on this issue is contradictory, and it cannot be ruled out that hormones, which are not cytoreductive, produce a temporary effect limited to the period of amenorrhea that occurs because of anovulation and hypoestrogenism (4). Moreover, most of the drugs used postoperatively, including danazol and GnRH agonists, cause subjective and metabolic side effects, are costly, and should generally be withdrawn after a few months. Accordingly, the identification of safe alternatives to permit prolonged postsurgical medical treatment would be advantageous. Endometriosis is generally a localized disease but is currently managed with systemic medical therapies. The use of drugs administered locally and specifically aimed at pelvic organs could limit the metabolic impact without reducing antalgic efficacy. 305
2 An intrauterine device (IUD) releasing levonorgestrel (i.e., an Lng-IUD), a potent 19-nortestosterone derivative progestin, can induce amenorrhea with a different modality with respect to standard regimens. In fact, locally administered levonorgestrel has a profound effect on the endometrium, which becomes atrophic and inactive, although ovulation is usually not suppressed (5, 6). It has been demonstrated that insertion of an Lng-IUD may relieve the menstrual pain associated with recurrent endometriosis (7, 8). As no data are available on the postoperative use of this medicated device, we designed a pilot study to verify whether the frequency and severity of dysmenorrhea recurrence is reduced in women in whom an Lng-IUD is inserted immediately after laparoscopic surgery for endometriosis compared with women treated with laparoscopic surgery only. MATERIALS AND METHODS This open-label, parallel-group, randomized, controlled trial compared treatment with an Lng-IUD after laparoscopy for symptomatic endometriosis with postoperative expectant management. The main objective of the study was to evaluate the frequency and severity of dysmenorrhea 1 year after surgery. Dyspareunia and nonmenstrual pain as well as patient satisfaction were also assessed. Institutional review board approval was obtained, and the women gave their informed consent to the study. We considered parous women of 40 years who did not want children and who were undergoing first-line operative laparoscopy for symptomatic stage I IV endometriosis according to the revised American Fertility Society classification (9). Patients all reported disabling dysmenorrhea more than 6 months in duration. Patients were excluded if they had uterine or adnexal anomalies other than endometriosis (chronic pelvic inflammatory disease, leiomyomas, endometrial polyps, genital malformations, pelvic varices), used treatments for endometriosis other than nonsteroid antiinflammatory drugs in the 3 months before study entry (6 months for GnRH agonists), had contraindications to progestins, or were unwilling to tolerate menstrual changes. Each patient was asked to complete a questionnaire on the presence and severity of dysmenorrhea, deep dyspareunia, and nonmenstrual pelvic pain graded with a 0- to 3-point multidimensional categorical rating scale modified from the one devised by Biberoglu and Behrman (10), which defines dysmenorrhea according to loss of work efficiency and need for bed rest (absence of pain, 0; some loss of work efficiency, mild, 1; in bed part of 1 day, occasional loss of work, moderate, 2; in bed for 1 or more days, incapacitation, severe, 3); nonmenstrual pain according to various degrees of discomfort and use of analgesics (absence of pain, 0; occasional pelvic discomfort, mild, 1; noticeable discomfort for most of the cycle, moderate, 2; pain persisting during the cycle or requiring strong analgesics, severe, 3); and deep dyspareunia according to limitation of sexual activity (no discomfort, 0; tolerated discomfort, mild, 1; intercourse painful to the point of interruption, moderate, 2; intercourse avoided because of pain, severe, 3). The women were also requested to grade the severity of dysmenorrhea, nonmenstrual pelvic pain, and deep dyspareunia using a 100-mm visual analog scale, the left extreme of which indicates the absence of pain and the right one pain as bad as it could be; a score of 1 50 was considered mild pain, moderate pain, and severe pain. Subjects were recruited who had moderate or severe dysmenorrhea on both scales. Conservative surgery at laparoscopy was performed according to Cook and Rock (11) using mechanical instruments and electrosurgery only (2). Adhesions were sectioned with microscissors; the ovaries were completely mobilized; and endometriomas were evacuated, rinsed with normal saline, and excised by means of countertraction applied on the pseudocapsule and normal gonadal cortex with atraumatic microforceps. Hemostasis was achieved with limited application of bipolar current. After complete excision or coagulation of all endometriotic lesions, eligible subjects were randomized in a proportion of 1:1 to Lng-IUD insertion or expectant management. Treatment allocation was performed in accordance with a computer-generated randomization sequence using serially numbered, opaque, sealed envelopes. A medicated device that releases levonorgestrel 20 g/day over a period of 5 years (Mirena; Leiras Oy, Turku, Finland) was inserted immediately into the uterine cavity of patients allocated to the adjuvant therapy arm. After operative laparoscopy, the patients underwent follow-up visits every 3 months, at which time a gynecologic examination was performed, a history of the pattern of uterine bleeding was taken, and variations in pain symptoms intensity were recorded. When the Lng-IUD prevented regular flows, pain during erratic bleeding episodes was considered as dysmenorrhea. Subjects were withdrawn from the study if after surgery they used any type of hormone therapy that could affect the pain symptoms associated with endometriosis. At the 12- month evaluation, the women were requested to rate their overall degree of satisfaction with the treatment (very satisfied, satisfied, uncertain, dissatisfied, or very dissatisfied). The rates of recurrence of moderate to severe menstrual pain in the two study arms were compared using Fisher s exact test. Variations in pelvic symptoms were evaluated by computing pain scores on the multidimensional categorical rating and visual analog scales and comparing differences between baseline and final median scores in the two groups with the Mann-Whitney U test. When appropriate, the 95% confidence interval (95% CI) was calculated for the observed 306 Vercellini et al. Medicated IUD after surgery for endometriosis Vol. 80, No. 2, August 2003
3 TABLE 1 Age, parity, and endometriosis stage at previous surgery by treatment allocation. Postoperative Lng-IUD group n (%) differences. All statistical tests were two sided. P.05 was considered statistically significant. RESULTS Conservative surgery only group n (%) Age (y) 30 6 (30) 7 (35) (70) 13 (65) Parity 1 11 (55) 12 (60) 2 9 (45) 8 (40) Disease stage a I 2 (10) 1 (5) II 2 (10) 4 (20) III 9 (45) 6 (30) IV 7 (35) 9 (45) Note: Lng-IUD levonorgestrel-releasing intrauterine device. a According to the revised American Fertility Society Classification (9). Vercellini. Medicated IUD after surgery for endometriosis. Fertil Steril Seventy-seven women evaluated at our endometriosis outpatient clinic were eligible for the study, but 32 declined randomization and five were lost to follow-up. Twenty of the remaining patients were allocated to Lng-IUD insertion after laparoscopic treatment, and 20 to conservative surgery only. Baseline clinical characteristics of the women enrolled in the trial are shown in Table 1. The distribution of the study variables was similar in both groups. Displacement of the Lng-IUD was observed in one woman 5 months after insertion, based on visualization at specular examination of the caudal extremity of the Lng- IUD vertical arm at the external cervical os. One subject in each group was lost to follow-up (at 9 months in the Lng- IUD group and at 7 months in the surgery-only group). These patients were classified as treatment failures in the evaluation both of postoperative dysmenorrhea rate, the primary end point, and of satisfaction with treatment. However, they were excluded from analysis of symptoms scores and menstrual pattern variations because complete information from pain diaries was not available. At the 12-month evaluation, amenorrhea was reported by five (28%) of the remaining 18 women in the Lng-IUD arm, hypomenorrhea or spotting by nine (50%), and normal flows by four (22%). Median (interquartile range) dysmenorrhea visual analog and multidimensional categorical rating scale scores fell by 50 mm (35 65) and 1 point (1 2) in the postoperative Lng-IUD group and by 30 (25 40) and 1 (0 2) in the surgery-only group (P.012 and.021, respectively, Mann-Whitney U test; Table 2). According to an intention-to-treat analysis, postoperative moderate or severe dysmenorrhea recurrence was less frequent in the former group (2/20 subjects, 10%) than in the latter (9/20, 45%; P.03, Fisher s exact test; relative risk.22; 95% CI,.05 90). The absolute risk reduction of dysmenorrhea recurrence in subjects undergoing Lng-IUD insertion compared with those allocated to expectant management was 35% (95% CI, 9% 61%). This means that an Lng-IUD inserted postoperatively will prevent the recurrence of moderate or severe dysmenorrhea in one out of three patients (95% CI, 2 11) 1 year after surgery, with a relative risk reduction of 78%. Dyspareunia and nonmenstrual pain scores were also reduced to a greater extent with the postoperative use of Lng-IUD (Table 2). One or more side effects were reported by eight of the 20 patients allocated to Lng-IUD insertion (bloating in six, weight gain in six, headache in three, seborrhea and acne in two, breast tenderness in one, decreased libido in one, and pelvic pain in one). Side effects were deemed tolerable by the women, and removal of the IUD was not necessary except in the case of the displaced device. At 12 months, six (30%) patients in the surgery plus Lng-IUD group were very satisfied with the treatment received, nine (45%) were satisfied, two (10%) uncertain, one (5%) dissatisfied, and two (10%) very dissatisfied compared with three (15%), seven (35%), three (15%), five (25%), and two (10%) in the laparoscopic surgery-only group. Overall, 75% of subjects in the surgery plus Lng-IUD group were satisfied or very satisfied after 1 year of treatment compared with 50% in the surgery-only group. DISCUSSION In this pilot study, the use of an Lng-IUD after conservative surgery for symptomatic endometriosis significantly reduced the medium-term risk of recurrence of moderate or severe dysmenorrhea and offered a higher degree of patient satisfaction. These results are probably due to the amenorrhea or hypomenorrhea associated with endometrial atrophy induced in most women by the locally released levonorgestrel (6). In fact, we had previously demonstrated a major decrease in uterine bleeding as well as in pain at menstruation in women with endometriosis treated with the Lng-IUD (7). However, a general effect secondary to uterine absorption of the progestin cannot be excluded, especially considering the typical side effects reported by some women using the medicated device (5). Nevertheless, toxicology studies suggest that local delivery of progestins in depot formulations is safe and generally well tolerated and may offer advantages over systemic administration (12). Also, deep-thrust dyspareunia was relieved to a greater extent in the postoperative Lng-IUD group in comparison with the surgery-only group. The effect of the Lng-IUD on FERTILITY & STERILITY 307
4 TABLE 2 Pain symptom scores in patients with endometriosis before and 12 months after laparoscopic surgery according to treatment allocation and pain scale. a Postoperative Lng-IUD group Conservative surgery only group Visual analog Multidimensional Visual analog Multidimensional Dysmenorrhea (n 18) b (n 19) b Baseline values 79 (65 83) 2 (1 2) 77 (59 83) 2 (1 2) 12-month values 22 (12 39) 1 (0 1) 41 (21 58) 1 (1 1) Median reduction c 50 (35 65) 1 (1 2) 30 (25 40) d 1(0 2) e Deep dyspareunia f (n 9) (n 8) Baseline values 52 (30 69) 1 (0 1) 55 (35 71) 1 (0 2) 12-month values 16 (12 33) 0 (0 1) 34 (20 44) 1 (1 1) Median reduction c 31 (20 45) 1 (1 1) 15 (10 40) 1 (0 1) Nonmenstrual pain (n 5) (n 7) Baseline values 53 (40 62) 1 (1 1) 49 (25 70) 1 (0 2) 12-month values 31 (20 48) 1 (0 1) 36 (21 45) 1 (0 1) Median reduction c 17 (8 17) 0 (0 1) 10 (7 14) 0 (0 1) Note: Lng-IUD levonorgestrel-releasing intrauterine device. a Values are medians with interquartile ranges in parentheses. b n no. of subjects reporting the symptom. c Figures are baseline values minus 6-month values. d The between-group difference is statistically significant, P.012, Mann-Whitney U test. e The between-group difference is statistically significant, P.021, Mann-Whitney U test. f One patient in the postoperative Lng-IUD group and two in the conservative surgery only group reported no sexual activity. Vercellini. Medicated IUD after surgery for endometriosis. Fertil Steril pain at intercourse has already been demonstrated by Fedele et al. (8) and could be due to a receptor-mediated action of locally released levonorgestrel on deep endometriotic foci adjacent to the isthmus and uterine cervix. Differences in nonmenstrual pain were limited and of questionable clinical importance. This is not unexpected as ovulation, the main cause of the above symptom (13), is usually not suppressed in women with an Lng-IUD. The small sample size undoubtedly limits the strength of our findings. Because no literature data were available on which to base a predictable additional effect of the medicated IUD in preventing menstrual pain after conservative surgery, a preplanned power calculation would have been difficult to perform. However, our trial was designed as a pilot study to identify major differences in symptom relief. The number of subjects recruited was enough to identify as statistically significant the observed 35% absolute risk reduction in dysmenorrhea recurrence. Another potential bias of the study is the open-label design. Double blinding would have been preferable but was not feasible owing to local organizational and bureaucratic requirements. Furthermore, insertion of an inert, nonmedicated, simple Silastic IUD was deemed unethical because it could have increased the amount of blood flow and pain at menstruation, exposing women to potential morbidity without any therapeutic advantage. Completion of pain diaries and questionnaires by the women themselves should have avoided undue influences by the investigators. Pain variation was assessed with two types of scales: a visual analog scale that estimates the subjective perception of the symptom and a multidimensional categorical rating scale that reflects also the functional impairment associated with dysmenorrhea. In addition, the degree of satisfaction with treatment was evaluated to include recognition of the patient s point of view and to give adequate weight to side effects that may have a major impact on the health-related quality of life. Except in one case requiring removal because of displacement, the Lng-IUD was generally well tolerated. The limited severity of the side effects reported may be due to the lower progestin plasma levels detected in medicated IUD wearers compared with subjects taking the drug orally or SC (5, 6, 12). Insertion of a medicated device after conservative surgery for endometriosis may constitute an innovative, effective, safe, and convenient adjuvant treatment for the long-term reduction of risk of dysmenorrhea recurrence. As hormonal therapies are symptomatic, the possibility of prolonging treatment indefinitely would be a major achievement in the management of women with endometriosis. However, further trials are needed to verify whether the good results observed are maintained during the entire 5-year period of efficacy of the system. Moreover, our study was conducted 308 Vercellini et al. Medicated IUD after surgery for endometriosis Vol. 80, No. 2, August 2003
5 on a selected population, namely, parous women not wanting to conceive with dysmenorrhea as their only or main symptom. The Lng-IUD may not demonstrate the same antalgic activity or could constitute an inappropriate choice in other clinical settings. References 1. Vercellini P, Trespidi L, De Giorgi O, Cortesi I, Parazzini F, Crosignani PG. Endometriosis and pelvic pain: relation to disease stage and localization. Fertil Steril 1996;65: Crosignani PG, Vercellini P, Biffignandi F, Costantini W, Cortesi I, Imparato E. Laparoscopy versus laparotomy in conservative surgical treatment for severe endometriosis. Fertil Steril 1996;66: Vercellini P, De Giorgi O, Pisacreta A, Pesole A, Vicentini S, Crosignani PG. Surgical management of endometriosis. Baillière s Clin Obstet Gynaecol 2000;14: Vercellini P, Frontino G, De Giorgi O, Pietropaolo G, Pasin R, Crosignani PG. Pre- and post-surgical management of endometriosis. Obstet Gynecol Clin N Am 2003;30: Nilsson CG, Lahteenmaki T, Robertson DN, Luukkainen T. Plasma concentrations of levonorgestrel as a function of the release rate of levonorgestrel from medicated intrauterine devices. Acta Endocrinol 1980;93: Odlin V. Long-term experience of a levonorgestrel-releasing intrauterine system. Eur J Contracept Reprod Health Care 1996;1: Vercellini P, Aimi G, Paonazza S, De Giorgi O, Pesole A, Crosignani PG. A levonorgestrel-releasing intrauterine system for the treatment of dysmenorrhea associated with endometriosis: a pilot study. Fertil Steril 1999;72: Fedele L, Bianchi S, Zanconato G, Portuese A, Raffaelli R. Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis. Fertil Steril 2001;75: The American Fertility Society. Revised American Fertility Society classification of endometriosis: Fertil Steril 1985;43: Biberoglu KO, Behrman SJ. Dosage aspects of danazol therapy in endometriosis: short-term and long-term effectiveness. Am J Obstet Gynecol 1981;139: Cook AS, Rock JA. The role of laparoscopy in the treatment of endometriosis. Fertil Steril 1991;55: Jordan A. Toxicology of progestogens of implantable contraceptives for women. Contraception 2002;65: Vercellini P. Endometriosis: what a pain it is. Semin Reprod Endocrinol 1997;15: FERTILITY & STERILITY 309
Laparoscopic uterosacral ligament resection for dysmenorrhea associated with endometriosis: results of a randomized, controlled trial
FERTILITY AND STERILITY VOL. 80, NO. 2, AUGUST 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Laparoscopic uterosacral ligament
More informationLaparoscopic excision of recurrent endometriomas: long-term outcome and comparison with primary surgery
Laparoscopic excision of recurrent endometriomas: long-term outcome and comparison with primary surgery Luigi Fedele, M.D., a Stefano Bianchi, M.D., a Giovanni Zanconato, M.D., c Nicola Berlanda, M.D.,
More informationFarhana B. Lockhat, Mb.Ch.B., a Joseph E. Emembolu, F.R.C.O.G., b and Justin C. Konje, M.D. a
Serum and peritoneal fluid levels of levonorgestrel in women with endometriosis who were treated with an intrauterine contraceptive device containing levonorgestrel Farhana B. Lockhat, Mb.Ch.B., a Joseph
More informationEndometriosis. What you need to know. 139 Dumaresq Street Campbelltown Phone Fax
Endometriosis What you need to know 139 Dumaresq Street Campbelltown Phone 4628 5292 Fax 4628 0349 www.nureva.com.au September 2015 What is Endometriosis? Endometriosis is a condition whereby the lining
More informationNon-contraceptive Uses of the Levonorgestrel Intrauterine Device Elena Gates, MD http://www.mirena-us.com/pvs1/pri/whatisframe.html Progestin levels with LNG- IUS Lower plasma levels Mirena 150-200 pg/ml
More informationSurgical treatment of endometriosis: location and patterns of disease at reoperation
Surgical treatment of endometriosis: location and patterns of disease at reoperation Elizabeth Taylor, M.D., and Christina Williams, M.D. Division of Reproductive Endocrinology and Infertility, Department
More informationEndometriosis. *Chocolate cyst in the ovary
Endometriosis What is endometriosis? Endometriosis is a common condition in young women. It's chronic, painful, and it often progressively gets worse over the time. *Chocolate cyst in the ovary Normally,
More informationMANAGEMENT OF REFRACTORY ENDOMETRIOSIS
(339) MANAGEMENT OF REFRACTORY ENDOMETRIOSIS Serdar Bulun, MD JJ Sciarra Professor and Chair Department of Ob/Gyn Northwestern University ENDOMETRIOSIS OCs Teenager: severe dysmenorrhea often starting
More informationCarl Gustaf Nilsson, M.D. t:j: Hannu Allonen, M.D. Juan Diaz, M.D.II Tapani Luukkainen, M.D., Ph.D.t
FERTILITY AND STERILITY Copyright 0 1983 The American Fertility Society Vol. 39, No.2, February 1983 Printed in U.8A. Two years' experience with two levonorgestrel-releasing intrauterine devices and one
More informationCLEAR COVERAGE HYSTERECTOMY CHECKLISTS
CLEAR COVERAGE HYSTERECTOMY CHECKLISTS Click on the link below to access the checklist sheet. Abnormal Uterine Bleeding Adenomyosis Chronic Abdominal or Pelvic Pain Endometriosis Fibroids General Guidelines
More informationProduct Information. Confidence that lasts
Confidence that lasts What is Mirena? Inhibition of sperm motility and function inside the uterus and the fallopian tubes, preventing fertilization (Videla-Rivero et al. 1987). Section of system Levonorgestrel
More informationSurgical Interruption of Pelvic Nerve Pathways for Primary and Secondary Dysmenorrhea
Page: 1 of 7 Last Review Status/Date: June 2015 for Primary and Secondary Dysmenorrhea Description Two laparoscopic surgical approaches are proposed as adjuncts to conservative surgical therapy for the
More informationChapter 3. Renato Seracchioli Mohamed Mabrouk Clarissa Frascà Linda Manuzzi Luca Savelli Stefano Venturoli Fertil Steril Jul; 94(2):
Chapter 3 Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial Renato Seracchioli Mohamed Mabrouk Clarissa
More informationRenato Seracchioli, M.D., Mohamed Mabrouk, M.D., Clarissa Frasca, M.D., Linda Manuzzi, M.D., Luca Savelli, M.D., and Stefano Venturoli, M.D.
Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial Renato Seracchioli, M.D., Mohamed Mabrouk, M.D.,
More informationPalm Beach Obstetrics & Gynecology, PA
Palm Beach Obstetrics & Gynecology, PA 4671 S. Congress Avenue, Lake Worth, FL 33461 561.434.0111 4631 N. Congress Avenue, Suite 102, West Palm Beach, FL 33407 Endometriosis The lining of the uterus is
More informationCNGOF Guidelines for the Management of Endometriosis
CNGOF Guidelines for the Management of Endometriosis Anatomoclinical forms of endometriosis Definitions Endometriosis is defined as the presence of endometrial tissue containing both glands and stroma
More information1. Attia AM et al. Role of the levonorgestrel intrauterine system in effective contraception. Patient Prefer Adherence 2013; 7:
1 2 1. Attia AM et al. Role of the levonorgestrel intrauterine system in effective contraception. Patient Prefer Adherence 2013; 7: 777 85. 3 1. Wu JP et al. Extended use of the intrauterine device: a
More informationGonadotropin-releasing hormone agonist treatment before abdominal myomectomy: a controlled trial
FERTILITY AND STERILITY VOL. 79, NO. 6, JUNE 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Gonadotropin-releasing hormone
More informationSurgical Interruption of Pelvic Nerve Pathways for Primary and Secondary Dysmenorrhea. Original Policy Date
MP 4.01.10 Surgical Interruption of Pelvic Nerve Pathways for Primary and Secondary Dysmenorrhea Medical Policy Section OB/Gyn/Reproduction Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date
More informationLong-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial
Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial Renato Seracchioli, M.D., Mohamed Mabrouk, M.D., Clarissa Frasca, M.D., Linda Manuzzi,
More informationUnintended Pregnancy is Common LEARNING OBJECTIVES. Distribution Of Contraception Use By Women In The Us. Unintended Pregnancy And Contraceptive Use
3:45 4:30 pm Beyond the Pill: Long Acting Contraceptives and IUDs Presenter Disclosure Information The following relationships exist related to this presentation: Christine L. Curry, MD, PhD: No financial
More informationLaparoscopy and Endometriosis: Preventing Complications and Improving Outcomes. Luis C. Paez M.D.
Laparoscopy and Endometriosis: Preventing Complications and Improving Outcomes Luis C. Paez M.D. Assumptions Pelvic pain Not desiring immediate fertility H & P suggest endometriosis OC/NSAID failures Endo
More informationLEARNING OBJECTIVES. Beyond the Pill: Long Acting Contraception. Distribution Of Contraception Use By Women In The Us. Unintended Pregnancy is Common
4:15 5 pm Beyond the Pill: Long Acting Contraceptives and IUDs Presenter Disclosure Information The following relationships exist related to this presentation: Christine L. Curry, MD, PhD: No financial
More informationPre and post surgical medical therapy. Mauro Busacca M.D. Dept of Obstetrics and Gynecology University of Milan- Italy
Pre and post surgical medical therapy Mauro Busacca M.D. Dept of Obstetrics and Gynecology University of Milan- Italy introduction A disease is an open problem when two conditions are nor satisfied: The
More informationInternational Journal of Research in Pharmaceutical and Nano Sciences Journal homepage:
Review Article ISSN: 2319 9563 International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage: www.ijrpns.com A REVIEW ON INTRAUTERINE DEVICES Boddu Venkata Komali* 1, M. Kalyani
More informationDienogest compared with gonadotropin-releasing hormone agonist after conservative surgery for endometriosis
doi:10.1111/jog.13023 J. Obstet. Gynaecol. Res. Vol. 42, No. 9: 1152 1158, September 2016 Dienogest compared with gonadotropin-releasing hormone agonist after conservative surgery for endometriosis Yotaro
More informationEndometriosis Treatment & Management Medscape
Endometriosis Treatment & Management Medscape Updated: Apr 25, 2016 Author: G Willy Davila, MD; Chief Editor: Michel E Rivlin, MD more... Approach Considerations The dependence of endometriosis on the
More informationSurgical treatment of deep endometriosis and risk of recurrence
Journal of Minimally Invasive Gynecology (2005) 12, 508-513 Surgical treatment of deep endometriosis and risk of recurrence Michele Vignali, MD, Stefano Bianchi, MD, Massimo Candiani, MD, Giovanna Spadaccini,
More informationBuserelin acetate in the treatment of pelvic pain associated with minimal and mild endometriosis: a controlled study*
.. FERTILITY AND STERILITY Copyright 99 The American Fertility Society Vol. 59, No., March 99 Printed on acid-free paper in U.S.A. Buserelin acetate in the treatment of pelvic pain associated with minimal
More informationComparison of contraceptive ring and patch for the treatment of symptomatic endometriosis
Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis Paolo Vercellini, M.D., a Giussy Barbara, M.D., a Edgardo Somigliana, M.D., Ph.D., b Stefano Bianchi, M.D., c Annalisa
More informationPostoperative maintenance levonorgestrel-releasing intrauterine system and endometrioma recurrence A randomized controlled study
Accepted Manuscript Postoperative maintenance levonorgestrel-releasing intrauterine system and endometrioma recurrence A randomized controlled study Yi-Jen Chen, M.D., Ph.D., Teh-Fu Hsu, M.D., Ben-Shian
More informationEndometriosis and Infertility - FAQs
Published on: 8 Apr 2013 Endometriosis and Infertility - FAQs Introduction The inner lining of the uterus is called the endometrium and it responds to changes that take place during a woman's monthly menstrual
More informationSurgical Interruption of Pelvic Nerve Pathways for Primary and Secondary Dysmenorrhea
Surgical Interruption of Pelvic Nerve Pathways for Primary and Secondary Dysmenorrhea Policy Number: 4.01.17 Last Review: 11/2013 Origination: 11/2007 Next Review: 11/2014 Policy Blue Cross and Blue Shield
More informationLevosert levonorgestrel 20mcg/24hour intrauterine device
Levosert levonorgestrel 20mcg/24hour intrauterine device Verdict: Formulary inclusion: Formulary category: Restrictions: Reason for inclusion: Link to formulary: Link to medicine review summary: Levosert
More informationGayatrri Anipindi *, Vani I. Original Research Article. Abstract
Original Research Article Role of levonorgestrel releasing intrauterine device in management of heavy menstrual bleeding: A safe and effective option for all PALM COEIN variants Gayatrri Anipindi *, Vani
More informationBy: Dr. Safoura Rouholamin
By: Dr. Safoura Rouholamin Introduction Endometriosis as an enigmatic disease is most commonly found on the ovaries and presents with pelvic pain and infertility. laparoscopic stripping has been introduced
More informationApplication for inclusion of levonorgestrel - releasing IUD for contraception in the WHO Model List of Essential Medicines
Application for inclusion of levonorgestrel - releasing IUD for contraception in the WHO Model List of Essential Medicines 1. Summary statement of the proposal for inclusion LNG-IUS is an effective contraceptive;
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationWhat s New in Adolescent Contraception?
What s New in Adolescent Contraception? Abby Furukawa, MD Legacy Medical Group Portland Obstetrics and Gynecology April 29, 2017 Objectives Provide an update on contraception options for the adolescent
More informationLow-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial
ENDOMETRIOSIS Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial Tasuku Harada, M.D., a Mikio Momoeda, M.D., b Yuji Taketani,
More informationA Prospective Observational Study to Evaluate the Efficacy and Safety Profiles of Leuprorelin 3 Month Depot for the Treatment of Pelvic Endometriosis
SH SUEN & SCS CHAN A Prospective Observational Study to Evaluate the Efficacy and Safety Profiles of Leuprorelin 3 Month Depot for the Treatment of Pelvic Endometriosis Sik Hung SUEN MBChB, MRCOG Resident
More informationEndometriosis. A Guide for Patients PATIENT INFORMATION SERIES
Endometriosis A Guide for Patients PATIENT INFORMATION SERIES Published by the American Society for Reproductive Medicine under the direction of the Patient Education Committee and the Publications Committee.
More informationREPRODUCTIVE ENDOCRINOLOGY
REPRODUCTIVE ENDOCRINOLOGY FERTILITY AND STERILITY VOL. 76, NO. 2, AUGUST 2001 Copyright 2001 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in
More informationPublic Statement: Medical Policy Statement: Background:
ARBenefits Approval: 10/12/2011 Effective Date: 01/01/2012 Revision Date: Code(s): 58578, unlisted laparoscopy procedure, uterus Medical Policy Title: Surgical Interruption of Pelvic Nerve Pathways for
More informationEndometriosis. A Guide for Patients PATIENT INFORMATION SERIES
Endometriosis A Guide for Patients PATIENT INFORMATION SERIES Published by the American Society for Reproductive Medicine under the direction of the Patient Education Committee and the Publications Committee.
More informationCY Tse, AMK Chow, SCS Chan. Introduction
Effects of an extended-interval dosing regimen of triptorelin depot on the hormonal profile of patients with endometriosis: prospective observational study CY Tse, AMK Chow, SCS Chan Objective. To evaluate
More informationREPRODUCTIVE ENDOCRINOLOGY
REPRODUCTIVE ENDOCRINOLOGY FERTILITY AND STERILITY VOL. 82, NO. 1, JULY 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Treatment
More informationEndometriosis. Assoc.Prof.Pawin Puapornpong, Faculty of Medicine, Srinakharinwirot University.
Endometriosis Assoc.Prof.Pawin Puapornpong, Faculty of Medicine, Srinakharinwirot University. Endometriosis Definition: Ectopic Endometrial Tissue True Incidence Unknown:? 1-5% Does NOT Discriminate by
More informationLONG-ACTING REVERSIBLE CONTRACEPTION. Summary Tables
LONG-ACTING REVERSIBLE CONTRACEPTION Summary Tables Bridging the Divide: A Project of the Jacobs Institute of Women s Health June 2016 Table 1. Summary of LARC Methods Available Years Since Effective Copper
More informationlevonorgestrel 13.5mg intrauterine delivery system (Jaydess ) SMC No. (1036/15) Bayer
levonorgestrel 13.5mg intrauterine delivery system (Jaydess ) SMC No. (1036/15) Bayer 6 March 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises
More informationDifference Between PCOS and Endometriosis
Difference Between PCOS and Endometriosis www.differencebetween.com Key Difference PCOS vs Endometriosis Ovaries play an important role in the reproduction and the maintenance of the female body. They
More informationORILISSA (elagolix) oral tablet
ORILISSA (elagolix) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationMenstrual characteristics in Korean women with endometriosis: a pilot study
Original Article Obstet Gynecol Sci 2018;61(1):142-146 https://doi.org/10.5468/ogs.2018.61.1.142 pissn 2287-8572 eissn 2287-8580 Menstrual characteristics in Korean women with endometriosis: a pilot study
More informationNEW TREATMENTS FOR OVARIAN ENDOMETRIOMA
SEUD 2018 NEW TREATMENTS FOR OVARIAN ENDOMETRIOMA Ivo Brosens Giuseppe Benagiano Faculty of Medicine, KU Leuven, Belgium Sapienza University, Rome, Italy Hughesdon P.E. (1957) THE OVARIAN ENDOMETRIOMA
More informationThe Use of GnRH Agonists in the Treatment of Endometriomas With or Without Drainage
The Use of GnRH Agonists in the Treatment of Endometriomas With or Without Drainage Pages with reference to book, From 30 To 32 Sertac Batioglu, Havva Celikkanat, Mustafa Ugur, Leyla Mollamahmutoglu, Huseyin
More informationMenstrual Disorders & Ambulatory Gynaecology
Menstrual Disorders & Ambulatory Gynaecology Mr. Nagui Lewis Aziz M B, CH B, FRCOG Consultant Gynaecologist The Royal Oldham Hospital 01/09/2018 Heavy menstrual bleeding (HMB ) is a common problem responsible
More informationme LUTEINIZED UNRUPTURED FOLLICLE SYNDROME AND ENDOMETRIOSIS
FERTILITY AND STERILITY Copyright c 980 The American Fertility Society Vol. 33,, JanuaEY 980 Printed in U.S.A. me LUTEINIZED UNRUPTURED FOLLICLE SYNDROME AND ENDOMETRIOSIS W. PAULDMOWSKI, M.D.,.PH.D.*
More informationEndometrial ablation with a vaporizing electrode II. Clinical outcome of a pilot study
Acta Obstet Gynecol Scand 1998; 77: 688 693 Copyright C Acta Obstet Gynecol Scand 1998 Printed in Denmark all rights reserved Acta Obstetricia et Gynecologica Scandinavica ISSN 0001-6349 ORIGINAL ARTICLE
More informationEndometriosis: Correlation of Severity of Pain with Stages of Disease
Journal of Bangladesh College of Physicians and Surgeons Vol. 34, No. 3, July 2016 Endometriosis: Correlation of Severity of Pain with Stages of Disease TS CHOWDHURY a, N MAHMUD b, TA CHOWDHURY c Summary:
More informationContraception. Objectives. Unintended Pregnancy. Unintended Pregnancy in the US. What s the Impact? 10/7/2014
Contraception Tami Allen, RNC OB, MHA Robin Petersen, RN, MSN Perinatal Clinical Nurse Specialist Objectives Discuss the impact of unintended pregnancy in the United States Discuss the risks and benefits
More information1. Attia AM et al. Role of the levonorgestrel intrauterine system in effective contraception. Patient Prefer Adherence 2013; 7:
1 2 1. Attia AM et al. Role of the levonorgestrel intrauterine system in effective contraception. Patient Prefer Adherence 2013; 7: 777 85. 3 1. Wu JP et al. Extended use of the intrauterine device: a
More informationVaginal parturition decreases recurrence of endometriosis
Vaginal parturition decreases recurrence of endometriosis Carlo Bulletti, M.D., a Anna Montini, Ph.D., b Paolo Levi Setti, M.D., c Antonio Palagiano, M.D., d Filippo Ubaldi, M.D., e and Andrea Borini,
More informationunderstanding endometriosis Authored by Dr KT Subrayen Sponsored by
understanding endometriosis Authored by Dr KT Subrayen Sponsored by in this booklet What is Endometriosis? 1 What causes Endometriosis? 3 What does Endometriosis look like? 4 Common symptoms of Endometriosis
More informationCritical Appraisal of Endometriosis Management for Pain and Subfertility
Critical Appraisal of Endometriosis Management for Pain and Subfertility N. F. Zuberi,J. H. Rizvi ( Department of Obstetrics and Gynaecology, The Aga Khan University, Karachi. ) Introduction Endometriosis
More informationA prospective, randomized study comparing laparoscopic ovarian cystectomy versus fenestration and coagulation in patients with endometriomas
FERTILITY AND STERILITY VOL. 82, NO. 6, DECEMBER 2004 Copyright 2004 American Society for Reproductive Medicine ublished by Elsevier Inc. rinted on acid-free paper in U.S.A. A prospective, randomized study
More informationInstruction for the patient
WS 4 Case 3 STI and IUD Your situation Instruction for the patient You are 32 years old, divorced and have one child; you have just started a new relationship You underwent surgical resection of the left
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal myomectomy in leiomyoma management, 77 Abnormal uterine bleeding (AUB) described, 103 105 normal menstrual bleeding vs., 104
More informationHeavy Menstrual Bleeding. Mr Nick Nicholas MD FRCOG Grad Dip Law. Consultant Gynaecologist
Heavy Menstrual Bleeding Mr Nick Nicholas MD FRCOG Grad Dip Law. Consultant Gynaecologist Why is HMB so important? 1:20 women aged 30-49 consult their GP with HMB Once referred to gynaecologist, surgical
More informationMENSTRUAL PATTERNS AND WOMEN'S ATTITUDES FOLLOWING STERILIZATION BY FA LOPE RINGS*
FERTILITY AND STERILITY Copyright 1979 The American Fertility Society Vol. 31, No.6, June 1979 Printed in U.s.A. MENSTRUAL PATTERNS AND WOMEN'S ATTITUDES FOLLOWING STERILIZATION BY FA LOPE RINGS* LIDIA
More informationThe pharmacological management of ENDOMETRIOSIS
The pharmacological management of ENDOMETRIOSIS 18 Endometriosis is a gynaecological condition in which endometrial tissue is present outside the uterine cavity, causing cyclic symptoms and, often, reduced
More informationWhen love hurts. A systematic review on the effects of surgical and pharmacological treatments for endometriosis on female sexual functioning
AOGS SYSTEMATIC REVIEW When love hurts. A systematic review on the effects of surgical and pharmacological treatments for on female sexual functioning GIUSSY BARBARA 1, FEDERICA FACCHIN 2, MICHELE MESCHIA
More informationUterine-Sparing Treatment Options for Symptomatic Uterine Fibroids
Uterine-Sparing Treatment Options for Symptomatic Uterine Fibroids Developed in collaboration Learning Objective Upon completion, participants should be able to: Review uterine-sparing fibroid therapies
More information1. Ng M et a l. Global, regional, and national prevalence of overweight and obesity in children and adults during : A systematic analysis
1 2 3 1. Ng M et a l. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980 2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet
More informationA multi-centre, multinational, cross-sectional, incident case control study on Factors associated with the development of
A multi-centre, multinational, cross-sectional, incident case control study on Factors associated with the development of Endometrioma and deep infiltrating endometriosis Professor C. Chapron and the Group
More informationPost-operative use of oral contraceptive pills for prevention of anatomical relapse or symptomrecurrence after conservative surgery for endometriosis
Human Reproduction, Vol.24, No.11 pp. 2729 2735, 2009 Advanced Access publication on July 22, 2009 doi:10.1093/humrep/dep259 ORIGINAL ARTICLE Gynaecology Post-operative use of oral contraceptive pills
More informationEndometriosis-associated pelvic pain: evidence for an association between the stage of disease and a history of chronic pelvic pain*
F ERTILITY AND STERILITY Copyright " 1997 American Society for Reproductive Medicine Published by Elsevier Science Inc. Vo!. 68, No. 1, J uly 1997 Printed on acid -free paper in U. S. A. Endometriosis-associated
More informationPelvic Pain: Overlooked
EDUCATION EXHIBIT 3 Pelvic Pain: Overlooked and Underdiagnosed Gynecologic Conditions 1 CME FEATURE See accompanying test at http:// www.rsna.org /education /rg_cme.html LEARNING OBJECTIVES FOR TEST 1
More informationOriginal Article. Abstract
Original Article Frequency of endometriosis among infertile women and association of clinical signs and symptoms with the Laparoscopic staging of Endometriosis Urooj Bakht Khawaja, 1 Ameer Ali Khawaja,
More informationDr. Nancy Van Eyk Associate Professor, Dalhousie University Chief of Gynaecology, IWK Health Centre
Dr. Nancy Van Eyk Associate Professor, Dalhousie University Chief of Gynaecology, IWK Health Centre AUB Outline Terminology Classification/Etiology Assessment Treatment Referral to Gynaecology U c pt 4
More informationENDOMETRIAL ABLATION: TRENDS AND CHALLENGES IN 2017
ENDOMETRIAL ABLATION: TRENDS AND CHALLENGES IN 2017 Philippe Laberge MD FRCSC ACGE Professor Obstetrics and Gynecology Laval University Quebec, Canada Disclosures I have used products or done clinical
More informationValidation study of nonsurgical diagnosis of endometriosis
FERTILITY AND STERILITY VOL. 76, NO. 5, NOVEMBER 2001 Copyright 2001 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Validation study
More informationAnalysis of risk factors for the removal of normal ovarian tissue during laparoscopic cystectomy for ovarian endometriosis
Human Reproduction, Vol.24, No.6 pp. 1402 1406, 2009 Advanced Access publication on February 26, 2009 doi:10.1093/humrep/dep043 ORIGINAL ARTICLE Gynaecology Analysis of risk factors for the removal of
More informationDepartment of Obstetrics and Gynaecology, Royal Surrey County Hospital, Guildford, United Kingdom
FERTILITY AND STERILITY Vol. 62, No.4, October 1994 Copyright c 1994 The American Fertility Society Printed on acid-free paper in U. S. A. Prospective, randomized, double-blind, controlled trial of laser
More informationWendy Shen, MD, PhD Refresher Course for the Family Physician April 5, 2018 Coralville, Iowa
Wendy Shen, MD, PhD Refresher Course for the Family Physician April 5, 2018 Coralville, Iowa Objectives Distinguish the different types of IUDs Understand the mechanism of action and selection of candidates
More informationintractable dysmenorrhea are diagnosed with endometriosis. 5
Endometriosis From Identification to Management Endometriosis, a gynecologic disorder that typically affects women of childbearing age, can result in dysmenorrhea, deep dyspareunia, chronic pelvic pain,
More informationClinical Policy: Goserelin Acetate (Zoladex) Reference Number: CP.PHAR.171 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Zoladex) Reference Number: CP.PHAR.171 Effective Date: 10.01.16 Last Review Date: 11.17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of
More information- Linzagolix overall efficacy and safety maintained or improved at week 24
Final results of ObsEva SA Phase 2b EDELWEISS trial of Linzagolix show sustained efficacy and Bone Mineral Density safety, for the treatment of endometriosis-associated pain - Linzagolix overall efficacy
More informationTreatment options for primary and secondary dysmenorrhoea
PRESCRIBING IN PRACTICE Treatment options for primary and secondary dysmenorrhoea DIMITRIOS MAVRELOS AND ERTAN SARIDOGAN SPL Dysmenorrhoea affects up to half of young women and can adversely affect quality
More informationContraception and gynecological pathologies
1 Contraception and gynecological pathologies 18 years old, 2 CMI normal First menstruation at 14 years old Irregular (every 2/3 months), painful + She does not need contraception She is worried about
More informationPRESACRAL NEURECTOMY AND UTERINE NERVE ABLATION FOR PELVIC PAIN
PRESACRAL NEURECTOMY AND UTERINE NERVE ABLATION FOR PELVIC PAIN Protocol: PAI008 Effective Date: November 1, 2015 Table of Contents Page COMMERCIAL, MEDICARE & MEDICAID COVERAGE RATIONALE... 1 DESCRIPTION
More informationINFERTILITY CAUSES. Basic evaluation of the female
INFERTILITY Infertility is the inability to conceive after 12 months of unprotected intercourse. There are multiple causes of infertility and a systematic way to evaluate the condition. Let s look at some
More informationGynecologic Decision Making Based on Sonographic Findings
Gynecologic Decision Making Based on Sonographic Findings Mindy Goldman, MD Department of Obstetrics & Gynecology & Vickie A. Feldstein, MD Department of Radiology University of California, San Francisco
More informationEndometriosis د. نجمه محمود كلية الطب جامعة بغداد فرع النسائية والتوليد
Endometriosis د. نجمه محمود كلية الطب جامعة بغداد فرع النسائية والتوليد Objectives:- To know what is endometriosis The sites where it occur To explain its itiology & pathogenesis To know the clinical features
More informationChapter 100 Gynecologic Disorders
Chapter 100 Gynecologic Disorders Episode Overview: 1. Describe the presentation and RF for Adnexal torsion 2. List the imaging findings of adnexal torsion (US vs CT) 3. What is the management of adnexal
More informationWhat is Endometriosis?
What is Endometriosis? Obstetrics & Gynaecology Women & Children s Services This leaflet has been designed to give you important information about your condition / procedure, and to answer some common
More informationFrequency of menses. Duration of menses 3 days to 7 days. Flow/amount of menses Average blood loss with menstruation is 60-80cc.
Frequency of menses 24 days (0.5%) to 35 days (0.9%) Age 25, 40% are between 25 and 28 days Age 25-35, 60% are between 25 and 28 days Teens and women over 40 s cycles may be longer apart Duration of menses
More informationEndometrial Cancer Biopsy of the endometrium Evaluation of women of all ages
Endometrial Cancer Biopsy of the endometrium Evaluation of women of all ages Barbara S. Apgar, MD, MS Professor of Family Medicine University of Michigan Health System Ann Arbor, Michigan Cancer of the
More informationThe facts about Endometriosis
The facts about Endometriosis A specialist team of health professionals with the expertise to provide personalised and up to date treatment for women with endometriosis. Nurse Co ordinator Gynaecologists
More informationResults of implication of aromatase inhibitors in therapy of genital endometriosis Yarmolinskaya M. (Speaker), Bezhenar V., Molotkov A.
Results of implication of aromatase inhibitors in therapy of genital endometriosis Yarmolinskaya M. (Speaker), Bezhenar V., Molotkov A. Ott's Research Institute of Obstetrics, Gynecology and Reproductology,
More informationThe biology of menstrually related. Ovulation Suppression of Premenstrual Symptoms Using Oral Contraceptives REPORTS. Patricia J.
REPORTS Ovulation Suppression of Premenstrual Symptoms Using Oral Contraceptives Patricia J. Sulak, MD Abstract Managing premenstrual symptoms at the most fundamental level necessitates careful consideration
More information